Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ventas
(NYSE:VTR)
Intraday
$43.48
0.35
[0.81%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$43.48
0.35
[0.81%]
Last update: 1:05PM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 8 days from now on Wed May 1st, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Ventas Stock (NYSE:VTR)
Ventas Stock (NYSE: VTR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Shares of REITs are trading lower as Treasury yields rise following hotter-than-expected March inflation data.
Benzinga Newsdesk
-
Apr 10, 2024, 9:57AM
Friday, March 29, 2024
(VTR) - Analyzing Ventas's Short Interest
Benzinga Insights
-
Mar 29, 2024, 11:30AM
Monday, March 18, 2024
Cracking The Code: Understanding Analyst Reviews For Ventas
Benzinga Insights
-
Mar 18, 2024, 10:00AM
Evercore ISI Group Upgrades Ventas to Outperform, Announces $50 Price Target
Benzinga Newsdesk
-
Mar 18, 2024, 6:00AM
Monday, March 04, 2024
Ventas Enters Into Cooperation Agreement With Land & Buildings; Terms Not Disclosed
Benzinga Newsdesk
-
Mar 4, 2024, 8:19AM
Thursday, February 29, 2024
Invest Like Bill Gates with These REITs
Shay Boloor
-
Feb 29, 2024, 7:44AM
Monday, February 26, 2024
Key Takeaways From Ventas Analyst Ratings
Benzinga Insights
-
Feb 26, 2024, 7:00AM
Wells Fargo Downgrades Ventas to Equal-Weight, Announces $46 Price Target
Benzinga Newsdesk
-
Feb 26, 2024, 6:44AM
Wednesday, February 21, 2024
Wall Street's Most Accurate Analysts' Views On 3 Real Estate Stocks With Over 4% Dividend Yields
Avi Kapoor
-
Feb 21, 2024, 8:15AM
Friday, February 16, 2024
Pfizer's Expansion Sparks Boom for these Healthcare REITs
Shay Boloor
-
Feb 16, 2024, 9:21AM
Wednesday, February 14, 2024
Ventas Expects FY24 Normalized FFO Per Share Of $3.07-$3.18 (Est $3.21)
Benzinga Newsdesk
-
Feb 14, 2024, 4:20PM
Ventas Q4 Normalized FFO Per Share $0.76 Beats $0.75 Estimate, Sales $1.16B Beat $1.15B Estimate
Benzinga Newsdesk
-
Feb 14, 2024, 4:17PM
Earnings Scheduled For February 14, 2024
Benzinga Insights
-
Feb 14, 2024, 4:48AM
Tuesday, February 13, 2024
Shares of REIT stocks are trading lower amid a rise in Treasury yields, which could drive a rotation out of income-paying stocks.
Benzinga Newsdesk
-
Feb 13, 2024, 3:26PM
This REIT Could Skyrocket on Donald Trump's Presidential Bid
Shay Boloor
-
Feb 13, 2024, 9:36AM
Sunday, February 04, 2024
Analyst Initiates Coverage On 10 Healthcare REITs, But Which Ones Are Buys?
Ethan Roberts
-
Feb 4, 2024, 7:56AM
Tuesday, January 30, 2024
Deutsche Bank Initiates Coverage On Ventas with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk
-
Jan 30, 2024, 7:07AM
Wednesday, January 17, 2024
Shares of REITs are trading lower amid a rise in Treasury yields, which could weigh on dividend and income assets.
Benzinga Newsdesk
-
Jan 17, 2024, 2:41PM
Tuesday, January 16, 2024
Forecasting The Future: 4 Analyst Projections For Ventas
Benzinga Insights
-
Jan 16, 2024, 3:00PM
B of A Securities Upgrades Ventas to Buy, Raises Price Target to $53
Benzinga Newsdesk
-
Jan 16, 2024, 12:16PM
Thursday, January 11, 2024
Ventas Confirms Issues Statement Regarding Three Director Nominations By Land & Buildings Investment Management
Benzinga Newsdesk
-
Jan 11, 2024, 8:53AM
Wednesday, January 03, 2024
Mizuho Maintains Buy on Ventas, Raises Price Target to $56
Benzinga Newsdesk
-
Jan 3, 2024, 10:40AM
Monday, November 13, 2023
Wells Fargo Maintains Overweight on Ventas, Lowers Price Target to $47
Benzinga Newsdesk
-
Nov 13, 2023, 10:12AM
Thursday, November 09, 2023
Shares of REITs are trading lower amid a rise in Treasury yields, which could pressure dividend-paying stocks.
Benzinga Newsdesk
-
Nov 9, 2023, 3:46PM
Wednesday, November 08, 2023
Jim Cramer Asks Why The World's Largest Healthcare Products Company Has 'An Ill-Advised Strategy'
Lisa Levin
-
Nov 8, 2023, 8:35AM
Tuesday, November 07, 2023
Ventas, Welltower Have New Growth in Senior Housing Portfolios: Analyst Says What's Next
Priya Nigam
-
Nov 7, 2023, 11:57AM
Expert Ratings for Ventas
Benzinga Insights
-
Nov 7, 2023, 8:00AM
Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday
Lisa Levin
-
Nov 7, 2023, 7:50AM
Wedbush Upgrades Ventas to Outperform, Raises Price Target to $51
Benzinga Newsdesk
-
Nov 7, 2023, 7:20AM
Thursday, November 02, 2023
CORRECTION: Ventas Q3 Sales $1.15B
Benzinga Newsdesk
-
Nov 2, 2023, 5:47PM
Ventas Sees FY23 Normalized FFO $2.92-$3.02 Vs $2.96-$2.99 Prior
Benzinga Newsdesk
-
Nov 2, 2023, 5:16PM
Ventas Updates FY23 Normalized Per Share FFO Range From $2.96-$2.99 To $2.92-$3.02
Benzinga Newsdesk
-
Nov 2, 2023, 4:11PM
Ventas Q3 FFO $0.75 Down From $0.76 YoY, Sales $1.15B Beat $1.12B Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 4:09PM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Wednesday, October 11, 2023
Exane BNP Paribas Initiates Coverage On Ventas with Outperform Rating
Benzinga Newsdesk
-
Oct 11, 2023, 12:42PM
Tuesday, October 03, 2023
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
Benzinga Insights
-
Oct 3, 2023, 11:00AM
Wedbush Initiates Coverage On Ventas with Neutral Rating, Announces Price Target of $44
Benzinga Newsdesk
-
Oct 3, 2023, 8:02AM
Friday, September 22, 2023
Analysts: Healthcare REITs Show A Dichotomy Of Performance
Ethan Roberts
-
Sep 22, 2023, 1:37PM
BMO Capital Maintains Outperform on Ventas, Lowers Price Target to $51
Benzinga Newsdesk
-
Sep 22, 2023, 9:42AM
Wednesday, September 20, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
Benzinga Insights
-
Sep 20, 2023, 11:00AM
9 Analysts Have This to Say About Ventas
Benzinga Insights
-
Sep 20, 2023, 8:01AM
Raymond James Downgrades Ventas to Outperform, Lowers Price Target to $53
Benzinga Newsdesk
-
Sep 20, 2023, 7:27AM
Thursday, September 07, 2023
Morgan Stanley Maintains Equal-Weight on Ventas, Raises Price Target to $47
Benzinga Newsdesk
-
Sep 7, 2023, 8:39AM
Wednesday, August 30, 2023
6 Analysts Have This to Say About Ventas
Benzinga Insights
-
Aug 30, 2023, 9:01AM
JP Morgan Maintains Neutral on Ventas, Lowers Price Target to $48
Benzinga Newsdesk
-
Aug 30, 2023, 8:57AM
Friday, August 11, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Benzinga Insights
-
Aug 11, 2023, 11:00AM
B of A Securities Downgrades Ventas to Neutral, Lowers Price Target to $48
Benzinga Newsdesk
-
Aug 11, 2023, 9:27AM
Wednesday, August 09, 2023
RBC Capital Maintains Outperform on Ventas, Lowers Price Target to $53
Benzinga Newsdesk
-
Aug 9, 2023, 11:48AM
Friday, August 04, 2023
Ventas shares are trading lower after the company reported Q2 financial results.
Benzinga Newsdesk
-
Aug 4, 2023, 10:58AM
Thursday, August 03, 2023
Ventas Q2 EPS $0.75 Up From $0.72 YoY, Sales $1.11B Beat $1.09B Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 4:18PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch